Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305863 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Lei Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The First Affiliated Hospital of Hainan Medical University & Hainan Province Clinical Medical Center of Respirato…. Hauptthemen laut MEDLINE: Asthma, Rosuvastatin Calcium, AMP-Activated Protein Kinases, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hainan Province.
Abstract (Originalsprache)
The efficacy of rosuvastatin in reducing allergic inflammation has been established. However, its potential to reduce airway remodeling has yet to be explored. This study aimed to evaluate the efficacy of rosuvastatin in reducing airway inflammation and remodeling in a mouse model of chronic allergic asthma induced by sensitization and challenge with OVA. Histology of the lung tissue and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) showed a marked decrease in airway inflammation and remodeling in mice treated with rosuvastatin, as evidenced by a decrease in goblet cell hyperplasia, collagen deposition, and smooth muscle hypertrophy. Furthermore, levels of inflammatory cytokines, angiogenesis-related factors, and OVA-specific IgE in BALF, plasma, and serum were all reduced upon treatment with rosuvastatin. Western blotting was employed to detect AMPK expression, while immunohistochemistry staining was used to observe the expression of remodeling signaling proteins such as α-SMA, TGF-β, MMP-9, and p-AMPKα in the lungs. It was found that the activity of 5’-adenosine monophosphate-activated protein kinase alpha (AMPKα) was significantly lower in the lungs of OVA-induced asthmatic mice compared to Control mice. However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region. These results indicate that rosuvastatin can effectively reduce airway inflammation and remodeling in mice with chronic allergic asthma caused by OVA, likely due to the reactivation of AMPKα and a decrease in angiogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The First Affiliated Hospital of Hainan Medical University & Hainan Province Clinical Medical Center of Respiratory Disease, Haikou, China.
- NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine & The Second Affiliated Hospital, Hainan Medical University, Haikou, China.
- Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
ORCID-Profile: Feng-Ying Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hainan Province
Zitieren
APA
Zhang, L., Huang, F. Y., Dai, S. Z., Wang, L., Zhou, X., Zheng, Z. Y., Li, Q., Tan, G. H., & Wang, C. C. (2024). Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0305863
Vancouver
Zhang L, Huang FY, Dai SZ, Wang L, Zhou X, Zheng ZY, et al. Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0305863
BibTeX
@article{Zhang2024,
author = {Zhang, Lei and Huang, Feng-Ying and Dai, Shu-Zhen and Wang, Lin and Zhou, Xiangdong and Zheng, Zhen-You and Li, Qi and Tan, Guang-Hong and Wang, Cai-Chun},
title = {Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305863}
}
EUVIMED